共 50 条
- [1] Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trialLANCET REGIONAL HEALTH-WESTERN PACIFIC, 2023, 41Huo, YongChen, BeijianLian, QiufangWang, ShuqingLiu, LuLu, DiQu, YanlingZheng, GuanzhongLi, LipengJi, YuanYin, GuotianHuang, WenjunXie, YingYang, XinchunGao, XiufangAn, PeiXue, FengtaiLi, HaoyuDeng, HuanLi, LiPei, LijuanQian, Lei
- [2] EFFICACY AND SAFETY OF TAFOLECIMAB IN CHINESE PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (CREDIT-2): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIALJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1552 - 1552Zhou, YujieChai, MengHe, YongmingZhao, WangHan, XuebinZhao, GuoyanMa, XuepingQiao, PingAn, PeiLi, HaoyuYan, ShulingMa, QingyangDeng, HuanQian, Lei
- [3] Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2)BMC MEDICINE, 2023, 21 (01)Chai, MengHe, YongmingZhao, WangHan, XuebinZhao, GuoyanMa, XuepingQiao, PingShi, DongmeiLiu, YuyangHan, WeiAn, PeiLi, HaoyuYan, ShulingMa, QingyangDeng, HuanQian, LeiZhou, Yujie
- [4] Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2)BMC Medicine, 21Meng ChaiYongming HeWang ZhaoXuebin HanGuoyan ZhaoXueping MaPing QiaoDongmei ShiYuyang LiuWei HanPei AnHaoyu LiShuling YanQingyang MaHuan DengLei QianYujie Zhou
- [5] Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: A randomized, double-blind, placebo-controlled phase 3 trialATHEROSCLEROSIS, 2025, 403Lin, JieJi, YuanWang, GaopinMa, XuepingYao, ZhuhuaHan, XuebinChen, JieChen, JiyanHuang, WeiXu, GuangmaPeng, DaoquanYan, PeishiQiao, PingHe, YongmingTang, YidaWang, MinghuiZhang, MengqiYu, JianjunHao, YuMa, Changsheng
- [6] Design of Reach: Phase 3 randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in FSHDNEUROMUSCULAR DISORDERS, 2022, 32 : S104 - S104Tawil, R.Han, J.Wang, L.Vissing, J.van Engelen, B.Statland, J.Mellion, M.Shoskes, J.Morabito, C.Jiang, J.Webster, J.
- [7] Tamoxifen in Duchenne muscular dystrophy: A multicentre, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy 48-week trialNEUROMUSCULAR DISORDERS, 2022, 32Henzi, B.Schmidt, S.Nagy, S.Rubino-Nacht, D.Schaedelin, S.Putananickal, N.Hafner, P.Dorchies, O.Fischer, D.
- [8] Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimabPHARMACOLOGICAL RESEARCH, 2024, 207Zhang, YanyanPei, ZhaohuiChen, BeijianQu, YanlingDong, XiaolinYu, BingeWang, GuoqinXu, FangLu, DongmeiHe, ZhimeiChen, BenchaoMa, LeiWang, MaxLi, BaiyongXia, MichelleZheng, BoHuo, Yong
- [9] Design of a phase 3, randomized, double-blind, placebo-controlled, 48-week study to evaluate the efficacy and safety of cendakimab in adult and adolescent patients with eosinophilic esophagitisCONTEMPORARY CLINICAL TRIALS, 2024, 147Charriez, Christina M.Zhang, Sandrade Oliveira, Claudia H. M. C.Patel, VrundaOh, Young S.Hirano, IkuoSchoepfer, AlainDellon, Evan S.
- [10] Efficacy and safety of statin therapy in children with familial hypercholesterolemia -: A randomized, double-blind, placebo-controlled trial with simvastatinCIRCULATION, 2002, 106 (17) : 2231 - 2237de Jongh, SOse, LSzamosi, TGagné, CLambert, MScott, RPerron, PDobbelaere, DSaborio, MTuohy, MBStepanavage, MSapre, AGumbiner, BMercuri, Mvan Trotsenburg, ASPBakker, HDKastelein, JJP